Cure Model Analysis for Esophageal Cancer Radiotherapy Patients

A retrospective study of 801 patients with unresectable locally advanced esophageal squamous cell carcinoma treated at a Chinese hospital from 2014 to 2023. The research quantifies statistical cure using a mixture cure model, estimating a 10.4% cure fraction and a 6.7-year cure point, with external validation on 5,000 matched patients from the SEER database.

Use Cases

• Validate the estimated cure fraction and cure point using the SEER database validation cohort of 5,000 patients.
• Analyze the impact of treatment regimen (CRT vs. CRT+ICIs) on cure fraction and cure point.
• Model the relationship between patient BMI and the probability of statistical cure.
• Assess how age ≥65 years and chronic comorbidities correlate with a lower probability of cure.
• Compare cure point estimates (6.7 vs. 9.3 years) between the primary and SEER validation cohorts.

Strengths

• Analysis is based on a cohort of 801 patient records from a single institution.
• External validation was performed using a matched cohort of 5,000 patients from the SEER database.
• The study provides specific cure model outputs, including a 10.4% cure fraction and a 6.7-year cure point.

Limitations

• The dataset is small in scope, contained within a 16.9 KB document file.
• The underlying patient-level data is not directly accessible; only the study's aggregated results and analysis are presented.
• The primary cohort is from a single hospital in China, which may limit generalizability.

Provenance

Source

Affiliated Cancer Hospital of Zhengzhou University and the SEER database.

Collection Method

Retrospective study using a relative survival-based mixture cure modeling methodology.

Time Range

2014 to 2023 for the primary cohort.

Freshness

null

Geography

Primary cohort from China; validation cohort from the United States (SEER).